Page 83 - Haematologica - Vol. 105 n. 6 - June 2020
P. 83
PRIMA-1Met and AZA combination in TP53-mutant MDS/AML
A
BC
D
E
Figure 1. PRIMA-1Met (APR-246, APR) is active on TP53- mutated acute myeloid leukemia (AML) cell lines and the combination of APR and azacitidine (AZA) is synergistic. (A) Relative proliferation with increasing APR concentrations (10- 8 to 10-5 M) in SKM1, K562, KG1a, THP-1, and HL60 cell lines from day-0 to day-3. (B) Dose-response curves of APR for the five cell lines. (C) Dose-response curves of AZA for the five cell lines, and (D) at a low APR concentration (IC10). (E) The proliferation rate relative to the untreated control at day 3 with IC50 AZA with or without IC10 APR in the five cell lines indi- cated above. *P<0.05, **P<0.01.
haematologica | 2020; 105(6)
1541
